IL2 and melanoma: More recently, GD2 has been considered as a promising target for the treatment of melanoma patients using either CAR-T cell therapy [181] or the immunocytokine hu14.18-IL2, an anti-GD2 humanised mAb linked to two molecules of IL-2 and administered to patients with recurrent resectable stage III or IV melanoma [182].